Q32 Bio Inc. (NASDAQ:QTTB) Shares Bought by Deutsche Bank AG

Deutsche Bank AG boosted its holdings in Q32 Bio Inc. (NASDAQ:QTTBFree Report) by 699.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,018 shares of the company’s stock after acquiring an additional 21,890 shares during the period. Deutsche Bank AG owned 0.21% of Q32 Bio worth $86,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of QTTB. AXQ Capital LP purchased a new stake in Q32 Bio in the 4th quarter valued at approximately $36,000. Hussman Strategic Advisors Inc. acquired a new stake in shares of Q32 Bio during the 4th quarter worth about $36,000. Raymond James Financial Inc. purchased a new stake in shares of Q32 Bio during the fourth quarter worth about $37,000. Cubist Systematic Strategies LLC acquired a new position in shares of Q32 Bio in the fourth quarter valued at approximately $42,000. Finally, Savant Capital LLC acquired a new position in shares of Q32 Bio in the fourth quarter valued at approximately $53,000. Hedge funds and other institutional investors own 31.32% of the company’s stock.

Q32 Bio Stock Performance

Shares of NASDAQ:QTTB opened at $1.92 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53. Q32 Bio Inc. has a 12 month low of $1.38 and a 12 month high of $53.79. The firm has a market capitalization of $23.42 million, a PE ratio of -0.13 and a beta of -0.02. The business has a 50-day moving average of $1.72 and a two-hundred day moving average of $5.24.

Q32 Bio (NASDAQ:QTTBGet Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.33. As a group, research analysts forecast that Q32 Bio Inc. will post -12.32 earnings per share for the current year.

Analyst Ratings Changes

QTTB has been the subject of several recent analyst reports. Wells Fargo & Company lowered their target price on shares of Q32 Bio from $16.00 to $15.00 and set an “equal weight” rating for the company in a research note on Wednesday, March 12th. BMO Capital Markets downgraded Q32 Bio from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $22.00 to $3.00 in a research report on Tuesday, February 11th. Finally, Piper Sandler downgraded Q32 Bio from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $20.00 to $4.00 in a research report on Tuesday, February 11th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Q32 Bio presently has an average rating of “Hold” and a consensus price target of $24.71.

View Our Latest Report on Q32 Bio

Q32 Bio Profile

(Free Report)

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.

Read More

Want to see what other hedge funds are holding QTTB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Q32 Bio Inc. (NASDAQ:QTTBFree Report).

Institutional Ownership by Quarter for Q32 Bio (NASDAQ:QTTB)

Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.